drugset / Trial / NCT00311714

Safety, Tolerability and Pharmacokinetic Study of Biota-CS-8958

NCT00311714

RandomizedParallel-groupDouble-blindPrevention

Summary

This study will look at the safety, tolerability and what the body does to CS-8958 given to 40 healthy volunteers 18-55 years old. CS-8958 is a dry-powder investigational drug that is breathed into the lungs through an inhaler device. The researchers will collect information about any problems that volunteers have while taking the drug and about changes in blood pressure and how the heart is working. Volunteers will have breathing tests, physical examinations, and blood samples collected for laboratory tests. The researchers will also look at how much of the medication travels throughout the body versus how much stays only in the lungs. Doses of the medication will be tested at one level and then at higher and higher levels after a safety committee reviews the safety and tolerability information on volunteers prior to the next higher dose being given. Each volunteer will participate for up to 6 weeks from initial screening to the follow up visit and spend 7 days in the clinic.

Timeline

Start
2007-04
Primary completion
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Laninamivir Octanoate Small molecule 5 mg Other
Subject Laninamivir Octanoate Small molecule 10 mg Other
Subject Laninamivir Octanoate Small molecule 20 mg Other
Subject Laninamivir Octanoate Small molecule 40 mg Other

Indications